YELENA RYBAK: Open Payments
NPI 1952943458 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,457 in 51 payments from 18 companies in 2025. Trend: 2023 $1,221 · 2024 $1,046 · 2025 $1,457
Food & beverage: $1,457
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $224 |
| E.R. Squibb & Sons, L.L.C. | 7 | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $155 |
| Alnylam Pharmaceuticals Inc. | 2 | $147 |
| Medtronic, Inc. | 2 | $140 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Amgen Inc. | 6 | $88 |
| HEARTFLOW, INC. | 4 | $80 |
| Merck Sharp & Dohme LLC | 3 | $73 |
| Lilly USA, LLC | 2 | $52 |
Products named: Wegovy, CAMZYOS, JARDIANCE, ZENPEP, AMVUTTRA, COREVALVE EVOLUT R, REPATHA, FFRct.
Industry payments across PA — which companies pay providers there.
